Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study
{{output}}
Aims: Multiple myeloma (MM) is an incurable plasma cell malignancy. Daratumumab-lenalidomide-dexamethasone (DRd) and daratumumab-bortezomib-dexamethasone (DVd) are widely used in relapsed/refractory MM (RRMM) treatment. Although ... ...